GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunny Pharmtech Inc (ROCO:6676) » Definitions » Notes Receivable

Sunny Pharmtech (ROCO:6676) Notes Receivable : NT$0.0 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Sunny Pharmtech Notes Receivable?

Sunny Pharmtech's Notes Receivable for the quarter that ended in Dec. 2024 was NT$0.0 Mil.


Sunny Pharmtech Notes Receivable Historical Data

The historical data trend for Sunny Pharmtech's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunny Pharmtech Notes Receivable Chart

Sunny Pharmtech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial - - - - -

Sunny Pharmtech Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sunny Pharmtech Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Sunny Pharmtech Notes Receivable Related Terms

Thank you for viewing the detailed overview of Sunny Pharmtech's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunny Pharmtech Business Description

Traded in Other Exchanges
N/A
Address
No.255,Longyuan 1st Road, Hsinchu Science Park, Longtan District, Taoyuan, TWN, 325002
Sunny Pharmtech Inc is a specialty pharmaceutical company. It is now fully-integrated, doing research, development, and manufacturing on both API and finished-dose products, which includes orals, liquids, semi-solids, and parenterals.

Sunny Pharmtech Headlines

No Headlines